OPTINOSE INC (OPTN) Stock News
NASDAQ:OPTN - Nasdaq - US68404V1008 - Common Stock - Currency: USD
OPTN Latest News and Analysis
Monday's pre-market session: top gainers and losers
Discover the top movers in Monday's pre-market session and stay informed about market dynamics.
Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million
Preliminary XHANCE prescription growth rate from third quarter to fourth quarter 2024 estimated to be approximately 20%
Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million
Preliminary XHANCE prescription growth rate from third quarter to fourth quarter 2024 estimated to be approximately 20%...
Optinose Announces 1-for-15 Reverse Stock Split
Optinose Announces 1-for-15 Reverse Stock Split
YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and...
Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference
Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference
YARDLEY, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat...
Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights
Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights
Company reports Q3 2024 XHANCE net revenue of $20.4 million, an increase of 3% compared to Q3 2023 Company reports positive inflection in new...
Optinose Announces Reporting Date for Third Quarter 2024 Financial Results
Conference Call and Webcast to be held November 12, 2024, at 8:00 a.m. Eastern Time
Optinose Announces Reporting Date for Third Quarter 2024 Financial Results
Conference Call and Webcast to be held November 12, 2024, at 8:00 a.m. Eastern Time...
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
YARDLEY, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and...
Optinose Appoints Terry Kohler as Chief Financial Officer
Optinose Appoints Terry Kohler as Chief Financial Officer
YARDLEY, Pa., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat...
New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery
YARDLEY, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat...
Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference
YARDLEY, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat...
OPTN Stock Earnings: OptiNose Beats EPS, Misses Revenue for Q2 2024
OPTN stock results show that OptiNose beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Optinose Reports Second Quarter 2024 Financial Results and Recent Operational Highlights
Optinose Reports Second Quarter 2024 Financial Results and Recent Operational Highlights
Company reports Q2 2024 XHANCE net revenue of $20.5 million, an increase of 5% compared to Q2 2023 XHANCE has been added to Express Scripts’ national...
Optinose Announces Reporting Date for Second Quarter 2024 Financial Results
Conference Call and Webcast to be held August 8, 2024, at 8:00 a.m. Eastern Time
Optinose Announces Reporting Date for Second Quarter 2024 Financial Results
Conference Call and Webcast to be held August 8, 2024, at 8:00 a.m. Eastern Time...
7 Little-Known Penny Stocks That Can Turn $10K Into $1 Million
Check out these explosive penny stocks with massive growth potential that could turn a modest $10,000 investment into a life-changing $1 million.
Expanded Access to XHANCE with Addition to National Commercial Formularies
Expanded Access to XHANCE with Addition to National Commercial Formularies
YARDLEY, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat...
Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT)...
OPTN Stock Earnings: OptiNose Misses EPS, Beats Revenue for Q1 2024
OPTN stock results show that OptiNose missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
OPTN Stock Earnings: OptiNose Misses EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips OptiNose (NASDAQ:OPTN) just reported results for the first quarter of 2024.Opti...
Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights
Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights
Company reports Q1 2024 XHANCE net revenue of $14.9 million, an increase of 26% compared to Q1 2023 Company expects full year 2024 XHANCE net revenues...
Optinose Announces Reporting Date for First Quarter 2024 Financial Results
Conference Call and Webcast to be held May 14, 2024, at 10:00 a.m. Eastern Time